Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 18Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Leukemia, Lymphocytic, Chronic, B-Cell 2Vomiting 1Orbital lymphoma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

telitacicept 2talquetamab 1bu-zhong-yi-qi-tang 1Walk Test 1Sugammadex 1Robotic Surgical Procedures 1Rituximab 1Psychodrama 1Population Groups 1Plasma Exchange 1Neostigmine 1Mycophenolic Acid 1Muscle Stretching Exercises 1Immunoglobulins, Intravenous 1Immunoglobulins 1Exercise 1Control Groups 1Cognitive Behavioral Therapy 1Art Therapy 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Myasthenia Gravis × Rituximab × Clear all
NCT07071246 2025-07-17

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Tang-Du Hospital

Phase NA Active not recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡